Optimizing patient selection for secondary cytoreductive surgery in recurrent endometrial cancer

被引:0
|
作者
Vargiu, Virginia [1 ]
Rosati, Andrea [1 ,2 ]
Tortorella, Lucia [1 ]
Giannarelli, Diana [3 ]
Capozzi, Vito Andrea [4 ]
Gallotta, Valerio [1 ]
Gioe, Alessandro [1 ]
Di Stefano, Ettore [2 ]
Corrado, Martina [2 ]
Berretta, Roberto [4 ]
Cosentino, Francesco [5 ]
Scambia, Giovanni [1 ,2 ]
Fanfani, Francesco [1 ,2 ]
机构
[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Woman & Child Hlth & Publ Hlth, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Rome, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCCS, Facil Epidemiol & Biostat, Rome, Italy
[4] Univ Parma, Dept Med & Surg, Parma, Italy
[5] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Campobasso, Italy
关键词
Endometrial Neoplasms; Neoplasm Recurrence; Local; Cytoreduction surgical procedures; SURGICAL-MANAGEMENT;
D O I
10.1136/ijgc-2024-005383
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective This retrospective, multicenter, observational study aimed to refine patient selection criteria for secondary cytoreductive surgery in recurrent endometrial cancer. The objective was to identify preoperative predictors of complete cytoreduction, assess surgical complexity, and propose a preoperative predictive scoring system to identify suitable candidates for secondary cytoreductive surgery. Methods Data from 331 women with recurrent endometrial cancer were analyzed across three Italian centers from January 2010 to December 2021. Patients were categorized based on treatment received (medical treatment, diagnostic laparoscopy/examination under anesthesia, or secondary cytoreductive surgery). Preoperative predictors, surgical complexity, complications, and a predictive scoring system were assessed. Logistic regression and receiver operating characteristic analysis were used for statistical evaluation. Results Of the cohort, 56.2% underwent debulking surgery, 17.2% had diagnostic laparoscopy, and 26.6% received medical treatment. Patients undergoing secondary cytoreductive surgery were younger, with a lower body mass index, better performance status, and fewer comorbidities. Single site locoregional relapse was common in secondary cytoreductive surgery patients. Age <65 years, single site relapse, lymph node, and hematogenous relapse were independent predictors of complete cytoreduction. A predictive scoring system demonstrated a clear relationship between the score and the likelihood of complete cytoreduction. Conclusion This study identified age <65 years, single site recurrence, as well as nodal and hematogenous recurrence, as predictive factors for achieving optimal cytoreduction. A predictive scoring system incorporating these factors has been proposed to identify optimal candidates for secondary cytoreductive surgery in recurrent endometrial cancer. The scoring system showed promising predictive accuracy and could aid in refining the decision making process, ensuring appropriate patient selection for secondary cytoreductive surgery. Further prospective studies are warranted to validate and enhance the predictive model.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] The role of iterative cytoreductive surgery in recurrent ovarian cancer: survival outcomes: beyond secondary cytoreductive surgery
    Kim, Jeeyeon
    Lee, Jimin
    Son, Joo-Hyuk
    Kong, Tae-Wook
    Chang, Suk-Joon
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A182 - A183
  • [32] CLINICAL OUTCOME OF SECONDARY SURGERY IN RECURRENT ENDOMETRIAL CANCER
    Bellati, F.
    Papadia, A.
    Gasparri, M. L.
    Di Donato, V.
    Ditto, A.
    Martinelli, F.
    Lorusso, D.
    Merola, M.
    Panici, P. L. Benedetti
    Raspagliesi, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1560 - 1561
  • [33] Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection
    Onda, T
    Yoshikawa, H
    Yasugi, T
    Yamada, M
    Matsumoto, K
    Taketani, Y
    BRITISH JOURNAL OF CANCER, 2005, 92 (06) : 1026 - 1032
  • [34] Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection
    T Onda
    H Yoshikawa
    T Yasugi
    M Yamada
    K Matsumoto
    Y Taketani
    British Journal of Cancer, 2005, 92 : 1026 - 1032
  • [35] ASO Author Reflections: Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
    Claudia Marchetti
    Anna Fagotti
    Giovanni Scambia
    Francesca De Felice
    Annals of Surgical Oncology, 2021, 28 : 3264 - 3265
  • [36] ASO Author Reflections: Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
    Marchetti, Claudia
    Fagotti, Anna
    Scambia, Giovanni
    De Felice, Francesca
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (06) : 3264 - 3265
  • [37] Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer
    Schorge, John O.
    Wingo, Shana N.
    Bhore, Rafia
    Heffernan, Thomas P.
    Lea, Jayanthi S.
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2010, 108 (02) : 123 - 127
  • [38] Outcomes of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer
    Gockley, A. A.
    Cronin, A.
    Bookman, M. A.
    Burger, R. A.
    Cristea, M.
    Griggs, J. J.
    Mantia-Smaldone, G. M.
    Meyer, L. A.
    O'Malley, D. M.
    Wright, A. A.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 81 - 82
  • [39] Impact of FDG-PET in suspected recurrent ovarian cancer and optimization of patient selection for cytoreductive surgery
    Ebina, Y.
    Sakuragi, N.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S70 - S71
  • [40] SALVAGE CYTOREDUCTIVE SURGERY FOR PATIENTS WITH RECURRENT ENDOMETRIAL CANCER: WHO WILL GAIN BENEFITS FROM IT?
    Wang, H.
    Ren, Y.
    Shan, B. O. E. R.
    Shi, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)